西隴科學(002584.SZ):擬以1.22億元轉讓福君基因40.5%股權
格隆匯 5 月 7日丨西隴科學(002584.SZ)公佈,公司於2021年5月7日召開第五屆董事會第三次會議,審議通過了《關於轉讓福建福君基因生物科技有限公司部分股權的議案》,同意公司將控股子公司福建福君基因生物科技有限公司(“福君基因”)40.5%股權以人民幣1.22億元(或等值美元)的價格轉讓給Fulgent Investment Development Limited (Hong Kong) (“Fulgent”,或其指定的主體,如適用)。
此次股權轉讓完成後,公司合併財務報表的範圍將相應的發生變化,福君基因將不再納入公司合併報表範圍。公司對福君基因剩餘的長期股權投資轉為採用權益法核算。
經公司初步測算,公司此次股權轉讓將產生投資收益的區間為1.2億元至1.4億元(未經審計),將計入本次股權轉讓完成當年度的合併報表當期損益,最終數據以公司當年經審計的財務報吿數據為準,不會對公司未來經營狀況產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.